A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.

[1]  M. McCarter,et al.  Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  David C. Smith,et al.  Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Hillemanns,et al.  A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Christensen,et al.  HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. , 2012, Cancer letters.

[5]  Carmen Birchmeier,et al.  Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.

[6]  D. McDonald,et al.  MET and VEGF: synergistic targets in castration-resistant prostate cancer , 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[7]  Yongchang Shi,et al.  Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth , 2011, Molecular Cancer Therapeutics.

[8]  S. Kaye,et al.  The role of targeted therapy in ovarian cancer. , 2011, European journal of cancer.

[9]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[10]  D. Alberts,et al.  Clinical Trials in Recurrent Ovarian Cancer , 2011, International Journal of Gynecologic Cancer.

[11]  J. Christensen,et al.  HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. , 2010, Cancer research.

[12]  M. Friedlander,et al.  A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. , 2010, Gynecologic oncology.

[13]  B. Monk,et al.  Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Percy Ivy,et al.  Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[16]  G. Jayson,et al.  Antiangiogenic drugs in ovarian cancer. , 2009 .

[17]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Howard Mackey,et al.  Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Ozols,et al.  Challenges for chemotherapy in ovarian cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[23]  E. Petricoin,et al.  Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Secord,et al.  Antiangiogenic therapies in epithelial ovarian cancer. , 2011, Cancer control : journal of the Moffitt Cancer Center.

[25]  E. Lengyel,et al.  An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. , 2010, Neoplasia.